29 news items
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm
CKPT
HRT
OCGN
16 May 24
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
OCGN
15 May 24
' lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm
CKPT
HRT
OCGN
12 May 24
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
OCGN
10 May 24
the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual
Ocugen to Present at May 2024 Investor Conferences
OCGN
10 May 24
hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness
5wlybk4eshdl0cpnvsw5dvjfz3mdxx55y20d86d63ytlw3o3v0kzzroklnl
CKPT
HRT
OCGN
7 May 24
6jfjq4gr7z6ddqcr3hzik3pulhay7tm2ptbqxoh
OCGN
3 May 24
on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our
nsnuo504dia0njkrb4b8u3t9g1
OCGN
2 May 24
are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human
ctvrsxoxmsxuft9uinrwkml0ofkmgzanpn8pdenjsmzlch
DD
DYAI
HCA
29 Apr 24
—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3
l3ejod3tcbul9clfvmgxisojnsqq70bp 6f
OCGN
29 Apr 24
—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.
kc50xj3 806z2y
OCGN
29 Apr 24
of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3
vnj0kl hb
OCGN
26 Apr 24
that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT
herxxr 2vdfd
OCGN
19 Apr 24
the globe. We are making an impact on patients' lives through courageous innovation—forging new scientific paths that harness our unique intellectual
moipw4khy1c nwj4
OCGN
12 Apr 24
through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene
re7xa4r39 8rup
OCGN
11 Apr 24
, Inc. Luna Innovations Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up
gl87bbvt9fm
OCGN
10 Apr 24
on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough
ra24sqx6ja4sz6ijw7qylhbwpelaa0tm
OCGN
8 Apr 24
through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene
6vlf597oqs1zq5hvo1wkkd6t4y2xmmhfq0hrq 58kmn0fvonwjhx
OCGN
5 Apr 24
an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our
f45alu94poqqv96qsu9g1rx2d9rwjxblw4qu0a9po53n4fdfcp6u07t
OCGN
2 Apr 24
, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients' lives through courageous innovation—forging
ponwft2 pl99rjuelyao35j4rfdcjr3kkd9dsf
OCGN
1 Apr 24
an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our